Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07173-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Yang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Universi…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Positron-Emission Tomography, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Key R&D Program of China, National Natural Science Foundation of China, Guangdong Provincial People's Hospital.
Abstract (Originalsprache)
PURPOSE: PD-L1 PET imaging can provide a non-invasively and real-time assessment of PD-L1 expression status at tumor sites. This study aimed to evaluate the targeting efficacy and biodistribution of a novel peptide-based PD-L1 PET agent, [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P, in preclinical studies and human participants. METHODS: [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P was synthesized and the probe stability was analyzed in vitro and in vivo. Cellular uptake of the probe was evaluated using tumor cell lines with different PD-L1 expression levels. Small animal PET imaging and semi-quantitative studies were conducted in PC3, H1975 and A549 tumor-bearing mice models, with tumor PD-L1 expression confirmed through immunofluorescence and immunohistochemistry. Furthermore, [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging was performed in 1 healthy volunteer and 14 lung cancer patients to assess biodistribution and PD-L1 expression at tumor sites. RESULTS: [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P exhibited a radiochemical purity of > 99% and had good stability both in vitro and in vivo. In vitro cellular uptake and in vivo small animal PET imaging revealed the probe binding to PD-L1 with high affinity and specificity, consistent with the results of immunofluorescence and immunohistochemistry. In the clinical study involving 15 participants, [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P was proven safe with demonstrating low uptake in normal organs and physiologically excreting via the urinary system. Lung cancer patients with high PD-L1 expression (TPS 70-90%) exhibited higher tumor uptake and tumor-to-background ratios than those with negative or low PD-L1 expression (TPS < 1-10%), with SUVmax of 1.89-2.27 vs. 0.87-1.01, tumor-to-lung ratios of 4.73-7.68 vs. 1.61-2.35, and tumor-to-muscle ratios of 6.73-12.61 vs. 4.35-5.61. CONCLUSION: [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P showed promising as a PET agent to assess tumor PD-L1 expression in preclinical and first-in-human studies, offering a non-invasive, real-time and accurate tool to address clinical challenges in predicting and assessing the efficacy of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PET Center, Department of Nuclear Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
- Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China.
- Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Nanfang PET Center, Nanfang Hospital, Southern Medical University, 1838 Guangzhou Avenue North, Guangzhou, 510515, China. gtang0224@smu.edu.cn.
- Department of Pulmonary Surgery, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China. jiangbenyuan@gdph.org.cn.
ORCID-Profile: Lei Jiang
Förderung
- National Key R&D Program of China
- National Natural Science Foundation of China
- Guangdong Provincial People's Hospital
Zitieren
APA
Chen, Y., Hu, Y., Li, A., Zhang, G., Guo, D., Yao, X., Zeng, B., Tang, G., Jiang, B., & Jiang, L. (2025). Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07173-7
Vancouver
Chen Y, Hu Y, Li A, Zhang G, Guo D, Yao X, et al. Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07173-7
BibTeX
@article{Chen2025,
author = {Chen, Yang and Hu, Yinting and Li, Ao and Zhang, Guojin and Guo, Danyi and Yao, Xinchao and Zeng, Baozhen and Tang, Ganghua and Jiang, Benyuan and Jiang, Lei},
title = {Preclinical and first‑in‑human evaluation of [68Ga]Ga-DOTA-PEG2-Asp2-PDL1P PET imaging to assess tumor PD-L1 expression},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07173-7}
}
EUVIMED